【摘要】 目的：系统评价半夏白术天麻汤加减单独使用或与其他疗法联合应用治疗椎动脉型颈椎病(CSA)的临床疗效，为其临床应用提供循证学支持。方法：检索国内外主流文献数据库，搜索半夏白术天麻汤加减单独使用或与其他疗法联合应用(研究组)治疗CSA的随机对照试验(对照组为其他疗法),检索日期为建库至2022年11月22日。参照Cochrane手册5.1.0提供的标准评估文献质量及风险，应用EndNote X9.1软件进行文献管理，应用RevMan 5.4软件进行Meta分析。结果：最终纳入18篇文献，合计1 822例患者(研究组936例，对照组886例)。Meta分析结果提示，研究组CSA患者的临床总有效率(OR=3.45,95%CI=2.66～4.48,Z=9.34,P<0.000 01)、临床治愈率(OR=2.24,95%CI=1.83～2.73,Z=7.92,P<0.000 01)高于对照组，差异均有统计学意义；研究组CSA患者椎-基底动脉血流速度、CSA眩晕症状和头痛症状的改善效果优于对照组，差异均有统计学意义(P<0.05);安全性分析结果显示，两组治疗方案均具有良好的安全性。结论：半夏白术天麻汤加减单独使用或与其他疗法联合应用可以治疗CSA,且可加快椎-基底动脉血流速度，促进血液循环，有效减轻患者的眩晕、头痛等临床症状，安全性良好。更多还原

【Abstract】 OBJECTIVE: To systematically evaluate the clinical efficacy of modified Banxia Baizhu Tianma decoction alone or combined with other therapies in the treatment of vertebral artery type of cervical spondylosis(CSA), so as to provide evidence-based support for its clinical application. METHODS: The mainstream literature databases at home and abroad were retrieved for randomized controlled trials(the control group was given other therapies) of modified Banxia Baizhu Tianma decoction alone or combined with other therapies(research group) in the treatment of CSA from establishment of the database to Nov. 22nd, 2022. The quality and risk of the literature were evaluated by reference to the criteria provided in the Cochrane Manual 5.1.0, literature management was performed by using EndNote X9.1 software, and Meta-analysis was conducted by using RevMan 5.4 software. RESULTS: A total of 18 studies were enrolled, including 1 822 patients(936 patients in the research group and 886 patients in the control group). Results of Meta-analysis suggested that the total clinical effective rate(OR=3.45,95%CI=2.66-4.48,Z=9.34,P<0.000 01) and the clinical cure rate(OR=2.24,95%CI=1.83-2.73,Z=7.92,P<0.000 01) of CSA patients in the research group were higher than those in the control group, with statistically significant differences. The improvements of vertebral-basilar artery blood flow velocity, symptoms of dizziness and headache of CSA patients in the research group were better than those in the control group, with statistically significant differences(P<0.05). The results of safety analysis indicated that both therapeutic regimens had good safety.CONCLUSIONS: Modified Banxia Baizhu Tianma decoction alone or in combination with other therapies can treat CSA, which can improve the blood flow velocity of vertebrobasilar artery, promote blood circulation, effectively reduce the clinical symptoms such as vertigo and headache, with good safety.更多还原